The revenue miss and uncertain government funding outlook are the primary negatives, partially offset by the recent capital raise extending runway. Watch for updates on U.S. government funding decisions for the planned manufacturing facility and enrollment completion of the EscharEx VALUE trial by Q1 2027.
Drug in focus
MDWD drug pipeline →EscharEx
● Neutral Named in this 6-K- Impact
- Phase
- Phase 3
- Time to market
- If the Phase 3 VALUE trial reads out positive in 2H 2027, an FDA submission could follow in 2027-2028, with potential approval in 2028-2029 at the earliest, assuming no delays.
- Next catalyst
- None dated
What to watchThe next catalyst is the interim sample-size reassessment and enrollment completion of the Phase 3 VALUE trial, expected by end of Q1 2027. A positive interim could de-risk the program and support a sample-size reduction; a negative signal would raise doubts. The topline Phase 3 readout is expected in 2H 2027, which will be the true binary event for the stock. Q3 2026 earnings on November 12, 2026 may provide an enrollment update.
Price Chart
Executive Summary
MediWound reported Q3 2026 revenue of $3.6M, down 33% YoY from $5.4M, and a net loss of $0.46 per share vs $0.24 a year ago. Revenue missed the $6.7M consensus by 46%, and the company disclosed that a substantial portion of 2026 revenue depends on uncertain U.S. government funding for a planned manufacturing facility. The balance sheet was strengthened by a $17.25M public offering closed after quarter-end, providing cash runway through the EscharEx Phase III VALUE data readout expected in early 2027.
Key Financial Metrics
Key Facts
- Q3 2026 revenue $3.6M, down 33% YoY from $5.4M, missing $6.7M consensus
- Net loss $6.0M ($0.46 per share) vs $2.7M ($0.24 per share) a year ago
- Cash burn $28.3M in first nine months of 2026; cash fell to $28.4M from $53.6M at year-end 2025
- Closed $17.25M underwritten public offering in November 2026 (9.2% dilution vs Sept 30 shares)
- 2026 revenue outlook uncertain: substantial portion depends on U.S. government funding discussions
- EscharEx Phase III VALUE trial enrollment and interim assessment on track for Q1 2027
- NexoBrid had strongest quarterly revenue since launch per Vericel; BARDA procurement began in Q3
- U.S. DoW awarded $3.3M additional non-dilutive funding for NexoBrid room-temperature-stable formulation
Financial Impact
Revenue miss of $3.1M vs consensus (46% shortfall); net loss widened by $3.3M YoY; cash burn of $28.3M in 9 months; $17.25M gross proceeds from offering provide ~6 months of runway at current burn rate
Risk Factors
- Substantial portion of 2026 revenue dependent on uncertain U.S. government funding for manufacturing facility
- Cash burn rate of ~$28M over 9 months implies limited runway despite recent $17.25M offering
- Revenue decline driven by lower development services revenue from U.S. government; no visibility on recovery
- EscharEx Phase III trial still enrolling; no efficacy data until at least Q1 2027 interim analysis
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001178913-26-005154 |
| Document: zk2636401.htm | 0001178913-26-005154 |
| Document: 0001178913-26-005154-index-headers.html | 0001178913-26-005154 |
| Document: 0001178913-26-005154-index.html | 0001178913-26-005154 |
| Document: 0001178913-26-005154.txt | 0001178913-26-005154 |
| Earnings Context (Synthetic; results releases only) | 0001178913-26-005154 |
Track record
13 reports on MDWD
6 of 7 bullish or bearish reports moved the stock their way by T+5. Best: +20.80% at T+60 after the Mar 5, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 3/10 Entry $12.90 Now $13.55 +5.04% settles Nov 20
- Nov 12, 20264d ago 6-K Bearish 6/10 Viewing No price data
- Nov 12, 20264d ago Press Release Bearish 6/10 Entry $12.97 Now $13.55 −4.47% settles Nov 19
- Nov 5, 202611d ago 6-K Bearish 6/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
- Nov 5, 202611d ago 424B5 Bearish 5/10 Entry $13.33 to $12.97 Now $13.55 −1.65% ▲ +2.70% +5.99% vs SPY
- Nov 3, 202613d ago 424B5 Bearish 5/10 Entry $14.20 to $13.82 Now $13.55 +4.58% ▲ +2.68% +1.76% vs SPY
- Sep 22, 20267w ago Press Release Bullish 4/10 Entry $13.95 to $13.80 Now $13.55 −2.87% ▼ −1.08% +0.11% vs SPY
- Jun 2, 202623w ago Insider Cluster Bullish 4/10 Entry $13.76 to $14.30 Now $13.55 −1.53% ▲ +3.92% +6.89% vs SPY
- May 27, 202624w ago Press Release Bearish 5/10 Entry $14.33 to $13.73 Now $13.55 +5.44% ▲ +4.19% +4.66% vs SPY
- May 7, 202627w ago Press Release Neutral 1/10 Entry $17.27 to $16.25 Now $13.55 −21.54% ▼ −5.91% −7.41% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers